---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050415"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:09:24.362774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated

## Summary
- Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.
- Cash and investments $227M; company expects runway into 2027 under current plans.
- Nominated PM647 as AATD development candidate; IND/CTA on track for mid-2026 with clinical data in 2027.
- Wilson's Disease program PM577 on track for IND/CTA in H1 2026; initial data expected in 2027.
- Appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead strategy and partnerships.

## SEC filing metadata
- accession: 0001628280-25-050415
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/0001628280-25-050415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/prme-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050415
- JSON: https://secwatch.observer/filing/0001628280-25-050415.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.